Amid South Korea’s ongoing efforts to show case its homegrown biopharma technologies and draw foreign investment into the sector, it is essential to learn how potential investors outside the country view the domestic industry and what could be further improved to attract overseas capital and collaborations.
Novo Holdings’ Jee On Korea's Potential As Next Global Biotech Player
Believer In Korean Innovation
In this video interview, Novo Holdings’ Noel Jee shares his views on the Korean biotech industry and innovation, including how to draw more foreign investment into the sector.
More from South Korea
More from Focus On Asia
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.